Rapid gastrointestinal disease test ARIES®
Clostridium difficilestoolmolecular

rapid gastrointestinal disease test
rapid gastrointestinal disease test
rapid gastrointestinal disease test
rapid gastrointestinal disease test
rapid gastrointestinal disease test
rapid gastrointestinal disease test
rapid gastrointestinal disease test
Add to favorites
Compare this product
 

Characteristics

Applications
for gastrointestinal diseases
Micro-organism
Clostridium difficile
Sample type
stool
Analysis mode
molecular
Specificity

Min.: 94.2 %

Max.: 97 %

Sensitivity

Min.: 84.6 %

Max.: 94.2 %

Description

The ARIES® C. difficile Assay is an easy to use molecular assay for the direct detection of toxigenic Clostridium difficile nucleic acid in stool samples using a sample to answer platform Clostridium difficile infections (CDI) are potentially life-threatening health risks that tend to occur in people who have taken antibiotics or been admitted to hospitals. In fact, CDI accounts for 15-25% of all antibiotic associated diarrhea and is the most common cause of infectious diarrhea in a healthcare setting.1 The rising prevalence of these colitis-inducing infections is cause for concern, as is the estimated $1 billion in healthcare costs they cause.2

Catalogs

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.